Research programme: GPCR modulators - Heptares Therapeutics

Drug Profile

Research programme: GPCR modulators - Heptares Therapeutics

Alternative Names: anti-PAR2 mAb - Heptares Therapeutics; calcitonin gene-related peptide (CGRP) modulators - Heptares Therapeutics; CNS disorder therapeutics - Heptares Therapeutics; HTL 0022562; M1/M4 agonist - Heptares Therapeutics; mGlus NAM - Heptares Therapeutics; muscarinic M1 agonists - Heptares Therapeutics; Orexin OX1 receptor antagonist - Heptares Therapeutics; Orexin OX2 agonists - Heptares Therapeutics

Latest Information Update: 16 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heptares Therapeutics
  • Developer Allergan; Heptares Therapeutics; Medical Research Council; Shire
  • Class Antibodies; Small molecules
  • Mechanism of Action Adenosine A2 receptor antagonists; Adenosine A2A receptor antagonists; Calcitonin gene-related peptide antagonists; G protein-coupled receptor modulators; Metabotropic glutamate receptor 5 modulators; Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists; PAR 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cognition disorders; Migraine; Obsessive-compulsive disorders; Psychotic disorders
  • Research Atopic dermatitis
  • No development reported Anxiety disorders; Autistic disorder; CNS disorders; Depressive disorders; Drug abuse; Parkinson's disease; Sleep disorders; Unspecified

Most Recent Events

  • 07 Nov 2018 Heptares Therapeutics enters into a collaboration agreement with DyNAbind to develop GPCR modulators
  • 13 Mar 2018 Sosei regains worldwide rights from Teva to develop CGRP antagonists
  • 13 Mar 2018 Sosei plans a phase I trial in Migraine (In volunteers) in late 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top